Yes, patients can stop Tirzepatide treatment at any time under the guidance of their licensed medical provider. However, maintaining healthy eating habits, exercise, and long-term lifestyle changes is important for preserving weight loss results after discontinuing GLP-1 therapy or telehealth weight management treatment.

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic the gut hormone GLP-1, which is released after eating. They reduce appetite, slow gastric emptying, and signal the brain to feel fuller sooner. Originally developed for Type 2 diabetes, GLP-1 medications are now FDA-approved for chronic weight management. Semaglutide and tirzepatide are the most widely used. Clinical trials show average body weight reductions of 15–22% — the highest ever seen in pharmaceutical weight management.

GLP-1 therapy is clinically indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as Type 2 diabetes, hypertension, or sleep apnea. You should also have tried diet and exercise without sustained results and be committed to regular medical monitoring. Certain conditions may affect candidacy — we will confirm eligibility at your free consultation.

Tirzepatide is a GLP-1 and GIP medication designed to support medical weight loss by helping regulate appetite, reduce cravings, slow digestion, and improve blood sugar balance. Many patients using Tirzepatide through a telehealth weight loss program experience better portion control, reduced hunger, and sustainable fat loss when combined with healthy lifestyle changes and ongoing medical supervision.

Eligibility for Tirzepatide treatment is determined through a virtual medical consultation with a licensed telehealth provider. Patients who struggle with obesity, excess body weight, weight-related health concerns, or difficulty losing weight through diet and exercise alone may qualify for a personalized GLP-1 weight loss treatment plan based on their health history and goals.